Eating Disorders

This report summarises what Blossom’s database shows about psychedelic and rapid-acting treatments for eating disorders, and what it does not. The honest headline is a tension: eating disorders, anorexia nervosa above all, are among the most serious and least adequately treated conditions in psychiatry, which makes new research genuinely important, and yet the psychedelic evidence here is among the most preliminary and the most safety-sensitive in the entire field. Both things are true at once, and a responsible account has to hold them together.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. No psychedelic is approved for any eating disorder, and the studies described are early-stage, closely supervised research in a medically high-risk group. Eating disorders, especially anorexia, can be life-threatening, and the established treatments, psychological therapy with medical and nutritional care, save lives and should always come first. Please do not attempt anything described here outside a clinical trial. If you or someone you care about is struggling, reach out to a doctor or an eating-disorder support service now.

A word on scope and numbers. Blossom tracks a few dozen papers and trials under this topic, and those counts appear on the page. Many are protocols, mechanism pieces, qualitative work and studies of related conditions, so the number of completed clinical trials with results is very small, in the low single digits. Read the counts as a measure of rising interest, not of an established evidence base.

Why eating disorders are a serious, and serious-stakes, target

Eating disorders are not vanity or willpower; they are mental illnesses with a major physical toll. Anorexia nervosa in particular carries one of the highest mortality rates of any psychiatric disorder, through both medical complications and suicide, and has stubbornly limited treatment options, with no medication that reliably works for adults[1]Curr Psychiatry Rep, psychedelic-assisted therapy for eating disorders review (2022). Bulimia nervosa and binge eating disorder are more treatable, with cognitive behavioural therapy and, for some, medication, but relapse is common across all of them. This combination, high stakes and limited tools, is exactly why researchers are willing to investigate something as unconventional as psychedelic therapy, and also why they must do so with unusual care.

The mechanistic rationale is genuinely plausible. Eating disorders are marked by rigid, inflexible thinking, harsh self-judgement, distorted body perception and, very often, a history of trauma. These are the kinds of psychological patterns that psychedelic therapy, at least in theory, is supposed to be able to loosen. Plausibility is not proof, but it is more than wishful thinking, and it is part of why the early work has been taken seriously rather than dismissed.

The landmark study: safety first, efficacy unproven

The single most important study is small by design. In 2023, researchers gave ten women with anorexia nervosa, or in partial remission, a single 25 mg dose of psilocybin with psychological support, in a trial built to test safety, tolerability and feasibility rather than whether it worked[2]Nature Medicine, psilocybin anorexia nervosa feasibility study (2023). In a population where a racing heart or a dangerous drop in blood pressure is a real concern, the central result was reassuring: no clinically meaningful problems on heart tracings, vital signs, blood tests or measures of suicidality, and participants generally found the experience acceptable and meaningful.

It is essential to read that result for what it is. A feasibility study answers the question can this be done safely, not does this help. The changes in eating-disorder symptoms were exploratory, varied a lot between individuals, and came from a tiny group with no control arm. Some participants reported meaningful shifts; others did not. So the correct summary is that the study cleared the first essential hurdle, showing that with careful screening psilocybin can be given to medically fragile anorexia patients without obvious harm, while leaving the efficacy question wide open. That open question is what the larger, controlled trial now under way is designed to answer, and until it reports, claims that psilocybin treats anorexia are ahead of the evidence.

MDMA: a real but indirect signal, and a withdrawn trial

MDMA is often mentioned alongside eating disorders, and there is a real reason, but it needs to be stated carefully. The evidence comes from a secondary analysis of a randomised controlled PTSD trial, which found that MDMA-assisted therapy significantly reduced eating-disorder symptoms compared with placebo among people with severe post-traumatic stress[3]J Psychiatr Res, MDMA-AT and eating-disorder symptoms in PTSD RCT (2022). Because trauma sits underneath a great many eating disorders, this is a meaningful and plausible signal. But it was measured in people whose primary diagnosis was PTSD, using a screening questionnaire, not in a trial designed to treat an eating disorder.

Direct evidence is scarce, and the path has not been smooth. A dedicated multi-site trial of MDMA-assisted therapy for eating disorders was withdrawn before it produced results, and a small study in bulimia nervosa is only now starting. So while MDMA is a plausible candidate, especially for the substantial overlap between eating disorders and post-traumatic stress disorder, as a stand-alone eating-disorder treatment it has barely been tested. Anyone citing MDMA as an eating-disorder therapy is, at present, extrapolating from trauma data.

The safety question that makes this different

Most psychedelic indications share a generic safety profile. Eating disorders add a specific, serious wrinkle. Classic psychedelics and MDMA briefly raise heart rate and blood pressure and place a transient load on the cardiovascular system. In a healthy adult that is usually trivial; in someone underweight, with disturbed electrolytes and a heart already under strain from malnutrition, it is not. This is why trials in this area screen so rigorously, often require a degree of medical and weight stability before dosing, and monitor closely throughout, and it is the single biggest reason that self-experimentation in this group is genuinely dangerous rather than merely unwise.

There is a psychological dimension to the caution as well. Anorexia in particular often involves a degree of attachment to the illness and a distorted sense of the body, and the effects of a psychedelic are powerful and unpredictable. Done well, within a supported therapeutic frame, the hope is that this can be used to help; done carelessly, it could just as easily destabilise. That asymmetry, large potential downside in a fragile group, modest and unproven upside, is the heart of why caution here is not pessimism but proportion.

Reading this honestly

So where do eating disorders sit? They are one of the most compelling reasons to do this research and one of the least finished stories in it. The need is real and sometimes desperate; the rationale is sound; the first study showed that, handled carefully, psilocybin can be given safely to a dangerously ill group. But the most thorough reviews are clear that the evidence remains preliminary[4]J Psychopharmacol, psychedelics for eating disorders and BDD review (2022), there is no controlled proof that any psychedelic improves an eating disorder, the MDMA case is borrowed from trauma trials, and a flagship trial was withdrawn. For people living with an eating disorder, or those who love them, the truthful message is both hopeful and firm: this is a serious avenue of research worth following closely, it is not a treatment you can or should seek out today, and the proven, life-saving options, therapy with medical and nutritional care, remain where help begins.